Evrysdi (Risdiplam)
- Medicine Name: Evrysdi
- API: Risdiplam
- Dosage Form & Strength: Tablets: 5 mg & Oral Solution: 0.75 mg/mL
- Manufactured By: Roche
Evrysdi (risdiplam) is a survival of motor neuron 2 (SMN2) splicing modifier used for the treatment of pediatric and adult patients with spinal muscular atrophy (SMA).
Recommended Dosage: Evrysdi is administered orally (by mouth) once daily with or without food. Swallow tablets whole with water. Do not crush, chew, or cut the tablets. In infants who are breastfed, oral solution can be administered before or after breastfeeding. This medicine cannot be mixed with milk or formula. The recommended dosage is specified by age and body weight.
- For infants younger than 2 months: The recommended daily dose is 0.15 mg per kg of body weight, using the oral solution.
- For children aged 2 months to less than 2 years: The recommended dose is 0.2 mg/kg daily, and it should be taken as an oral solution.
- For children aged 2 years or older weighing less than 20 kg: They should receive 0.25 mg/kg of medicine daily, administered only in oral solution form.
- For individuals aged 2 years and older weighing 20 kg or more: A fixed dose of 5 mg daily is recommended, taken as either oral solution or tablet.
If a dose of Evrysdi is missed, administer it as quickly as you remember, but only if it’s within 6 hours of the usual time. If more than 6 hours have passed, do not take the missed dose (skip it). Take the next scheduled dose at the regular time the very next day. Never take two doses on the same day.
- Treatment with Risdiplam 5 mg tablets or 0.75 mg/mL oral solution may affect how some other therapeutic drugs are removed from the body. It can impact MATE1 and MATE2-K transporter proteins, so consult your healthcare provider (HCP) before taking any additional medicines or supplements with this medicine.
- This therapeutic drug may cause harm to the unborn baby if used during pregnancy. Women who can become pregnant should discuss with their healthcare professional (HCP) about the risks and effective use of birth control while on treatment and for 30 days after stopping treatment.
- It is not known if this therapeutic drug passes into human breast milk. Women who are breastfeeding should consult their clinician to discuss whether to stop breastfeeding or stop treatment with this medicinal product, considering the probable risks to the baby.
- Evrysdi 5 mg tablets or 0.75 mg/mL oral solution may affect fertility in both males and females. Men should not father a child while receiving treatment with this drug and for 5 months after stopping treatment. Women should consider birth control during treatment and for one month after.
- This therapeutic drug is approved for use in children aged two months and older. Dosage generally depends on the child’s weight as well as age. It is very important to follow the prescribed dose and discuss any concerns with the pediatrician.
What documents are required to import EVRYSDI to India?
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patient ID proof (issued by the government of India)
How does the order get confirmed?
- A valid prescription from the Doctor
- Import permit if applicable
Is EVRYSDI available in India?
- On availability of Evrysdi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
- On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
EVRYSDI can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
Indian Pharma Network can source EVRYSDI (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Evrysdi®?
Risdiplam is the Generic Name for the trade name drug Evrysdi®.
What is the Manufacturer’s Name of Evrysdi®?
Evrysdi® is manufactured by Roche.
Is Evrysdi® approved by the FDA?
Yes, Evrysdi® is approved by the FDA. Date of first Approval: August 7, 2020.
What is the dosage and form of Evrysdi® supplied?
Evrysdi® is supplied in Tablets: 5 mg & oral solution: 60 mg of risdiplam as a powder for constitution to provide a 0.75 mg/mL solution for oral administration. This medicinal product can only be obtained with a prescription.
What are the most common side effects of Evrysdi®?
In patients with later-onset SMA, the most common side effects include diarrhea, fever, and rash.
In patients with infantile-onset SMA, common side effects include upper and lower respiratory tract infections, vomiting, constipation, and cough.
How much does the Evrysdi® 5 mg Tablet or 0.75 mg/mL Oral Solution cost in India?
Prices of Evrysdi may fluctuate over time due to market dynamics and regulatory changes. To get the most accurate and latest details on Evrysdi 5 mg tablet – 0.75 mg/mL oral solution cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
Can Evrysdi® 5 mg Tablets or 0.75 mg/mL Oral Solution be available in SAARC countries?
Apart from Gulf countries, Evrysdi® 5 mg or 0.75 mg/mL Oral Solution can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Evrysdi® in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.
Is it safe to buy Evrysdi® 5 mg Tablets or 0.75 mg/mL Oral Solution online in India?
Yes, one can buy Evrysdi 5 mg – 0.75 mg/mL oral solution online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Evrysdi® through legal channels.
What are the storage conditions of Evrysdi® 5 mg tablets or 0.75 mg/mL Oral Solution?
Store this medicine at room temperature (15 to 30°C). Protect it from moisture and light. Do not freeze. Keep the bottle well closed and out of children’s reach.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.